Every figure this model derived for MRNA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 171,000,000 | PaymentsToAcquirePropertyPlantAndEquipment |
2026-06-30 |
| cash | 5,138,000,000 | CashAndCashEquivalentsAtCarryingValue |
2026-06-30 |
| current assets | 5,815,000,000 | AssetsCurrent |
2026-06-30 |
| current liabilities | 2,534,000,000 | LiabilitiesCurrent |
2026-06-30 |
| equity | 6,761,000,000 | StockholdersEquity |
2026-06-30 |
| interest expense | 10,000,000 | InterestPaidNet |
2025-12-31 |
| ocf | -1,073,000,000 | NetCashProvidedByUsedInOperatingActivities |
2026-06-30 |
| revenue | 2,228,000,000 | RevenueFromContractWithCustomerExcludingAssessedTax |
2026-06-30 |
| sbc | 462,000,000 | ShareBasedCompensation |
2026-06-30 |
The figures themselves rather than their scores — what somebody looking up MRNA on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | -118.0 |
| current ratio | 2.6 |
| current ratio reported | 2.29 |
| deferred revenue growth | 35.32 |
| dilution pct | 1.3 |
| ev owner earnings | -30.77 |
| ev sales | 23.56 |
| fcf margin | -55.83 |
| growth cv | 2.19 |
| interest cover | -332.0 |
| operating margin | -149.01 |
| owner earnings margin | -76.57 |
| revenue growth | -27.62 |
| revenue growth per share | -28.55 |
| roic | -116.52 |
| rpo growth | -65.04 |
| rule of 40 | -176.63 |
| sbc pct revenue | 20.74 |
What this model itself distrusts about MRNA's figures. Written by the derivation as it ran, not added afterwards.